Open Comment Period | IASLC

Open Comment: IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapy

Please click the button below to access the non-disclosure agreement (NDA), which must be signed prior to accessing the manuscript and providing your comments.

Upon signing and submitting of the NDA*, you will receive a link to the manuscript in your email. Please follow that link to access the manuscript and provide comments.   
* If you need to download the NDA please do so and return via email to MPR@iaslc.org. 
For questions please email MPR@iaslc.org. 

Open Comment NDA


This article outlines recommendations on how to best process lung cancer resection specimens and define major pathologic response and complete pathologic response following neoadjuvant therapy.

This manuscript* and its recommendations are based upon the opinion from 41 multidisciplinary expert members of the International Association for the Study of Lung Cancer (IASLC), primarily from the Pathology Committee. In addition, a literature review was conducted on neoadjuvant therapy as it relates to pathologic assessment. A set of lead authors drafted the manuscript, which was then reviewed by all co-authors, resulting in a series of eight recommendations.

These recommendations are intended as guidance for clinical trials, although it is hoped they can also inform good clinical practice outside of clinical trials and ultimately improve consistency of pathologic assessment of treatment response.

*IASLC Multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens following neoadjuvant therapy.